← Back to China
Sino Biopharmaceutical
1177.HK · Healthcare · Hang Seng · HKD
Latest observation
Q4 2025
Reality Gap Values
RG8 Q4 2025 2.2
RG10 Q4 2025 2.0
RG12 Q4 2025 1.8
Trend (RG10 vs prior period)
++ Strongly IncreasingSupporting Data (Q4 2025)
| Market Capitalisation | HKD 103.8B |
| Tangible Equity (TE) | HKD 23.6B |
| Smoothed Earnings G (4yr avg) | HKD 2.9B |
| Net Income (this period) | HKD 0B |
Values in HKD billions.
Historical RG Overview
| Period | Mkt Cap (HKD B) | TE (HKD B) | RG8 | RG10 | RG12 |
|---|---|---|---|---|---|
| Q4 2025 | 103.8 | 23.6 | 2.2 | 2.0 | 1.8 |
| Q4 2024 | 45 | 23.6 | 1.0 | 0.8 | 0.8 |
| Q4 2023 | 43.3 | 23.6 | 1.0 | 0.9 | 0.8 |
RG10 Trend
No chart data available.
Data Note
Computed via yfinance. Historical end-of-quarter closing price × current shares outstanding. Older quarters estimated from annual NI / 4. Approximation.
All data is illustrative and for research purposes only. Not investment advice. Market cap for historical periods approximated as shares outstanding × year-end closing price (H-share basis).